Citadel Advisors’s KALA BIO KALA Stock Holding History

Citadel Advisors’s Portfolio KALA Stock Details KALA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4	Closed	-$2K	–	15190
2022 Q3	$2K	Hold	4	–	–	﹤0.01%	12425
2022 Q2	$3K	Sell	4 -10	-71%	-$15.7K	﹤0.01%	12707
2022 Q1	$47K	Sell	14 -4	-22%	-$10.5K	﹤0.01%	12831
2021 Q4	$55K	Sell	18 -2	-10%	-$9.28K	﹤0.01%	13194
2021 Q3	$132K	Sell	20 -2	-9%	-$17.3K	﹤0.01%	12529
2021 Q2	$286K	Sell	22 -6	-21%	-$94.3K	﹤0.01%	11384
2021 Q1	$479K	Sell	28 -4	-13%	-$78.1K	﹤0.01%	9768
2020 Q4	$546K	Buy	32 +18	+129%	+$339K	﹤0.01%	7969
2020 Q3	$272K	Buy	14 +9	+180%	+$207K	﹤0.01%	8297
2020 Q2	$142K	Sell	5 -2	-29%	-$56.7K	﹤0.01%	8783
2020 Q1	$152K	Hold	7	–	–	﹤0.01%	8281
2019 Q4	$66K	Hold	7	–	–	﹤0.01%	8682
2019 Q3	$70K	Sell	7 -16	-70%	-$195K	﹤0.01%	8613
2019 Q2	$373K	Buy	23 +14	+156%	+$232K	﹤0.01%	7259
2019 Q1	$189K	Buy	9 +4	+80%	+$71.1K	﹤0.01%	8250
2018 Q4	$55K	Sell	5 -1	-17%	-$17.3K	﹤0.01%	8470
2018 Q3	$137K	Buy	+6	New	+$183K	﹤0.01%	8442

Other funds holding KALA

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Citadel Advisors's KALA Position: Q1 2026 in Review

Citadel Advisors increased its KALA BIO (KALA) stake by 399% in Q1 2026, buying an estimated $95.3K and bringing the position to 5,633 shares worth $48.8K. The position accounts for ﹤0.01% of the portfolio, ranked #12410.

Citadel Advisors first reported a position in KALA in Q4 2018 and has held it in 18 quarters since. The position peaked at $2.18M in Q1 2020. 28 funds tracked by Wall St. Rank hold KALA as of Q1 2026.

Citadel Advisors held 5,633 shares of KALA BIO worth $48.8K as of Q1 2026.
Citadel Advisors bought 4,505 KALA BIO shares in Q1 2026, an estimated $95.3K.
KALA BIO made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12410 holding.
Citadel Advisors first reported a position in KALA BIO in Q4 2018 and has held it in 18 quarters since.
Citadel Advisors's KALA BIO position peaked at $2.18M in Q1 2020.
28 funds tracked by Wall St. Rank held KALA BIO as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.